AZ32
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407913

CAS#: Unknown

Description: AZ32 is an orally bioavailable and blood-brain-barrier penetrating ATM inhibitor (AZ32) that radiosensitizes intracranial gliomas in mice. AZ32 was highly efficient in vivo as radiosensitizer in syngeneic and human, orthotopic mouse glioma model compared with AZ31. AZ32 is the first ATMi with oral bioavailability shown to radiosensitize glioma and improve survival in orthotopic mouse models.


Price and Availability

Size
Price

100mg
USD 850
1g
USD 3350
Size
Price

200mg
USD 1450
2g
USD 5450
Size
Price

500mg
USD 2150
5g
USD 7650

AZ32, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 407913
Name: AZ32
CAS#: Unknown
Chemical Formula: C20H16N4O
Exact Mass: 328.1324
Molecular Weight: 328.375
Elemental Analysis: C, 73.15; H, 4.91; N, 17.06; O, 4.87


Synonym: AZ32; AZ-32; AZ 32.

IUPAC/Chemical Name: N-methyl-4-(6-phenylimidazo[1,2-a]pyrazin-3-yl)benzamide

InChi Key: LCRTUEXVVKVKBD-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H16N4O/c1-21-20(25)16-9-7-15(8-10-16)18-11-23-19-12-22-17(13-24(18)19)14-5-3-2-4-6-14/h2-13H,1H3,(H,21,25)

SMILES Code: O=C(NC)C(C=C1)=CC=C1C2=CN=C3C=NC(C4=CC=CC=C4)=CN32


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage. A major impediment for clinical implementation is that current inhibitors have limited CNS bioavailability, thus, the goal was to identify ATM inhibitors (ATMi) with improved CNS penetration.


References

1: Karlin J, Allen J, Ahmad SF, Hughes G, Sheridan V, Odedra R, Farrington P, Cadogan EB, Riches LC, Garcia-Trinidad A, Thomason AG, Patel B, Vincent J, Lau A, Pike KG, Hunt TA, Sule A, Valerie NCK, Biddlestone-Thorpe L, Kahn J, Beckta JM, Mukhopadhyay N, Barlaam B, Degorce SL, Kettle J, Colclough N, Wilson J, Smith A, Barrett IP, Zheng L, Zhang T, Wang Y, Chen K, Pass M, Durant ST, Valerie K. Orally bioavailable and blood-brain-barrier penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice. Mol Cancer Ther. 2018 May 16. pii: molcanther.0975.2017. doi: 10.1158/1535-7163.MCT-17-0975. [Epub ahead of print] PubMed PMID: 29769307.